GET DAILY SIGNALSNRx Pharmaceuticals (NRXP) Stock Declines -17.6% Over 30 Days Despite FDA Approval
Key Takeaways
- NRXP shares fell roughly 17.6% over the last 30 days, sliding from a closing price of $2.89 on October 8, 2026, to $2.38 on November 6, 2026.
- The decline occurred even as the U.S. Food and Drug Administration approved NRx's preservative-free ketamine injection on October 30, 2026, ahead of its November 10 goal date.
- A UBS downgrade to Sell, a New York Times-related controversy over the preservative benzethonium chloride, and heavy post-approval profit-taking all pressured sentiment.
- Over the trailing three months, NRXP has fallen roughly 29%, extending a longer multi-month downtrend despite steady pipeline progress.
- Broader influences include a roughly $11.2 million DARPA contract for NRX-101 combined with robotic TMS and second-quarter 2026 results that missed estimates, against a still-unprofitable, cash-constrained profile.
NRx Pharmaceuticals (NRXP) Company Background and Focus Areas
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company advancing therapies through its NMDA receptor platform, targeting central nervous system conditions such as suicidal depression, chronic pain, and post-traumatic stress disorder. Its primary candidates include NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRX-100 carries Fast Track Designation for suicidal ideation in depression, and NRX-101 has Breakthrough Therapy Designation for suicidal bipolar depression. The firm also runs HOPE Therapeutics, a network of interventional psychiatry clinics, and NRx Defense Systems, which targets federally funded initiatives pairing NRX-101 with robotic transcranial magnetic stimulation. I reviewed comparable names in the space using Tickeron’s AI Screener to gauge relative positioning.
NRx Pharmaceuticals (NRXP) Recent Stock Performance: 30 Days and Quarter
Over the past 30 days, NRXP dropped approximately 17.6%, moving from a close of $2.89 on October 8, 2026, to $2.38 on November 6, 2026. Price action was uneven, holding near $2.85–$2.95 through mid-October before several sharp, high-volume declines in late October and early November, with a short rebound to $2.49 on November 4. The broader trend shows further weakness. From a close of $3.35 on August 10, 2026, the stock has declined about 29% over three months, after an early-August spike above $4 intraday.
Factors Influencing NRXP Stock in the Past Month
The standout development was the FDA’s October 30 approval of the preservative-free ketamine injection for U.S. pain and anesthesia markets, coming ahead of the November 10 GDUFA target. The stock nevertheless dropped sharply on the news, closing down roughly 14% on heavy volume after a premarket jump. Earlier in the period, UBS downgraded the shares to Sell on October 20. Around the same time, a New York Times report and related claims about toxicity data on benzethonium chloride prompted a management rebuttal calling the assertions unfounded and stressing the preservative-free formulation. Wolfe Research started coverage with an Outperform rating on October 15, while Ascendiant Capital Markets kept a Buy and raised its price target early in the month. I checked recent signals on this name through Tickeron’s AI Daily Buy/Sell Signals for additional context.
Drivers Behind NRXP Performance Over the Quarter
The extended downtrend ties to both fundamentals and financing considerations. Second-quarter 2026 results, released in August, showed a net loss of $0.18 per share that exceeded consensus estimates along with a revenue shortfall, underscoring the pre-commercial stage. NRx finished June with roughly $26.7 million in cash and continues to access an at-the-market equity facility, keeping dilution risk in focus for this small-cap name. Positive steps included a late-September award of an initial $11.2 million DARPA contract to NRx Defense Systems for evaluating robotic TMS with NRX-101 in treatment-resistant depression. The ketamine ANDA advanced through first-cycle review, manufacturing validation, and two-year stability data. These items have yet to offset selling pressure and risk-off sentiment in speculative biotech.
Key Items to Monitor for NRXP Going Forward
Near-term focus centers on commercial rollout of the newly approved preservative-free ketamine, including supply and early sales traction. Investors will also track the NDA path for NRX-100 as a branded depression treatment, with management pointing toward a possible 2027 decision, plus enrollment and initial data from the federally funded MIND1 and SPARC-TMS trials of NRX-101. Quarterly results, cash position, and any further equity raises remain important. Competitive pressures in ketamine and depression markets, including Johnson & Johnson’s Spravato, add another layer. Regulatory and trial outcomes continue to carry risk for this clinical-stage company.
Integrating AI Tools Into My Research Workflow
When evaluating names like NRXP, I occasionally cross-reference automated strategies on Tickeron’s platform to see how quantitative signals align with my fundamental read. The Trending AI Robots page highlights some of the stronger-performing bots across different approaches and timeframes, offering a concise way to compare data-driven methods without replacing core analysis. This helps flag patterns I might otherwise overlook in fast-moving biotech names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NRXP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NRXP turned positive on November 06, 2026. Looking at past instances where NRXP's MACD turned positive, the stock continued to rise in 35 of 39 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NRXP's RSI Oscillator exited the oversold zone, 34 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 66 cases where NRXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +14.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXP advanced for three days, in 191 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXP as a result. In 69 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 50-day moving average for NRXP moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NRXP entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-606.141) is very low in comparison to the industry average of (3.482). P/E Ratio (-4.667) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
Advertisement